- 5-R-Rivaroxaban
-
- $8.00 / 1kg
-
2024-04-25
- CAS:865479-71-6
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: g-kg-tons, free sample is available
|
| | 5-R-Rivaroxaban Basic information |
| Product Name: | 5-R-Rivaroxaban | | Synonyms: | 5-R-Rivaroxaban;5-Chloro-N-[[(5R)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-2-thiophenecarboxamide;R-Rivaroxaban;(R)-5-chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)thiophene-2-carboxamide;ent-Rivaroxaban;(R)-Rivaroxaban, ent-Rivaroxaban;Rivaroxyban R-isomer;R-ENANTIOMER OF RIVAROXABAN | | CAS: | 865479-71-6 | | MF: | C19H18ClN3O5S | | MW: | 435.88 | | EINECS: | | | Product Categories: | | | Mol File: | 865479-71-6.mol |  |
| | 5-R-Rivaroxaban Chemical Properties |
| Melting point | >227°C (dec.) | | Boiling point | 732.6±60.0 °C(Predicted) | | density | 1.460 | | storage temp. | Refrigerator | | solubility | Acetonitrile (Slightly, Heated, Sonicated), DMSO (Slightly, Sonicated), Methanol | | form | Solid | | pka | 13.36±0.46(Predicted) | | color | White to Off-White |
| | 5-R-Rivaroxaban Usage And Synthesis |
| Uses | ent-Rivaroxaban is the R-isomer of Rivaroxaban (R538000), which is a novel antithrombotic agent. A highly potent and selective, direct FXa inhibitor. | | Biological Activity | 5-r-rivaroxaban is a selective inhibitor of human factor xa with ic50 value of 0.7 nmol/l [1].factor xa is a serine endopeptidase enzyme and plays an important role in the convergence point of the intrinsic and extrinsic pathways in blood coagulation system [2].5-r-rivaroxaban is an oral, direct factor xa inhibitor and the inhibition is species-dependent. when tested with purified factoe xa from human or rabbit, 5-r-rivaroxaban showed similar affinity with ic50 value of 0.7 nmol/l and 0.8 nmol/l, respectively, while had a ic50 value as low as 3.4 nmol/l when tested with rat factor xa [1].pre-treated anaesthetised rat model with intravenous 5-r-rivaroxaban at a dose of 2 mg/kg, and after bleeding initiated intravenous treated with rfviia (100/400 μg/kg), pcc (25/50 u/kg) or apcc (50/100 u/kg), the result showed that 5-r-rivaroxaban pre-treatment significantly shorten bleeding time and clotting time compared with 5-r-rivaroxaban alone treated group [2]. similar results were obtained when tested with rabbit model [1].it has been reported that 5-r-rivaroxaban is a promising drug for atrial fibrillation, venous thromboembolism or thromboembolic disorders in clinic [3] [4] [1]. | | references | [1]. perzborn, e., et al., rivaroxaban: a new oral factor xa inhibitor. arterioscler thromb vasc biol, 2010. 30(3): p. 376-81.
[2]. perzborn, e., et al., reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. thromb haemost, 2013. 110(1): p. 162-72.
[3]. beyer-westendorf, j., et al., efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ortho-tep registry. j thromb haemost, 2012. 10(10): p. 2045-52.
[4]. palareti, g., et al., clinical management of rivaroxaban-treated patients. expert opin pharmacother, 2013. 14(5): p. 655-67. |
| | 5-R-Rivaroxaban Preparation Products And Raw materials |
|